# Palivizumab

## Synagis inj 50mg/0.5mL

| TAH Drug Code      | [ISYNA1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ISYNA1)                                                                                                                                                                                                                                                                 |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease, including infants with bronchopulmonary dysplasia, a history of premature birth (<=35 weeks gestational age), & children with hemodynamically significant congenital heart disease. |
| Dosing             | IM, 15 mg/kg/month.                                                                                                                                                                                                                                                                                                                      |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                            |
| Contraindications  | Hypersensitivity to palivizumab or humanized monoclonal antibodies.                                                                                                                                                                                                                                                                      |
| Adverse Effects    | Upper respiratory infections, otitis media, rhinitis, rash, pain, hernia, increased SGOT, pharyngitis.                                                                                                                                                                                                                                   |
| Pregnancy          | No (Limited) Human Data â€“ No Relevant Animal Data                                                                                                                                                                                                                                                                                        |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                            |

